Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2015 | Poster presentation

P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine

Authors: Andrea Negro, Lidia D'Alonzo, Noemi Lala, Paolo Martelletti

Published in: The Journal of Headache and Pain | Special Issue 1/2015

Login to get access

Excerpt

OnabotulinumtoxinA (Botox®) is the first and so far the only treatment to receive a specific license for prevention of chronic migraine (CM). In our Headache Clinic the therapy with onabotulinumtoxinA is routinely administered to CM patients on a daily basis since 2001. Preventive treatment with onabotulinumtoxinA was offered to all patients that were 1) adults; 2) fulfilling the ICHD-II criteria for CM with or without analgesic overuse; and 3) with contraindications or lack of efficacy or tolerability to other preventive drugs. …
Literature
1.
Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ: Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010, 50 (9): 1406-1418.CrossRefPubMed
Metadata
Title
P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine
Authors
Andrea Negro
Lidia D'Alonzo
Noemi Lala
Paolo Martelletti
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue Special Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-16-S1-A137

Other articles of this Special Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue

Invited speaker presentation

Vestibular migraine

Poster presentation

P056. Clinical case: headache as a symptom of another disease detector

Invited speaker presentation

Kynurenine pathway metabolites in migraine

Oral presentation

O062. Post ambulatory surgery headache in patients affected from primary headaches: a comparison with the general population

Poster presentation

P043. Hyperechogenicity of the periaqueductal gray in chronic migraine and episodic migraine as a potential marker of progressive dysfunction: preliminary results with transcranial sonography

Invited speaker presentation

Laser evoked potentials and central sensitization in migraine